Insulet price to free cash flow PODD
Market value divided by free cash flow over the last twelve months, since 2023.
- Today, Nov 2, 2026
- 36.3×
- 3-year median
- 72.7×
- Against its 3-year history
- 17th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 24.2× to 474×
- Peer median
- 18.8×
Insulet's price to free cash flow is 36.3× as of Nov 2, 2026.
That is below its 3-year median of 72.7×, lower than on 83% of days in the last 3 years.
Over that time it ranged from 24.2× in May 2026 to 474× in Aug 2023.
The median for 10 medical instruments and supplies stocks of a similar size is 18.8×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 36.3× | 24.2× | 48.0× |
| 2025 | 47.9× | 47.9× | 87.4× |
| 2024 | 81.9× | 66.8× | 353× |
| 2023 | 374× | 267× | 474× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Insulet's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| PODDInsulet | 36.3× |
| GMEDGlobus Medical | 14.1× |
| ALGNAlign Technology | 17.3× |
| COOCooper Companies | 17.2× |
| PENPenumbra | 58.6× |
| SOLVSolventum | n/m |
| MSAMSA Safety | 20.3× |
| HAEHaemonetics | 18.8× |
| MMSIMerit Medical Systems | 24.8× |
| VNTVontier | 12.9× |
| BMIBadger Meter | 31.6× |
| Peer median | 18.8× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Insulet
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.